<s id="wsj_2382.1"> 30
0 	 7 	 (S[dcl]\NP)/S[dcl] 	 1 	 Food said
6 	 2 	 N/N 	 1 	 Nesbit Drug
6 	 3 	 N/N 	 1 	 Nesbit Administration
6 	 4 	 N/N 	 1 	 Nesbit spokesman
6 	 5 	 N/N 	 1 	 Nesbit Jeff
6 	 7 	 (S[dcl]\NP)/S[dcl] 	 1 	 Nesbit said
9 	 8 	 NP[nb]/N 	 1 	 agency the
9 	 10 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 agency has
9 	 11 	 ((S[pt]\NP)/PP)/NP 	 1 	 agency turned <XB>
10 	 7 	 (S[dcl]\NP)/S[dcl] 	 2 	 has said
11 	 10 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 turned has
11 	 12 	 (S\NP)\(S\NP) 	 2 	 turned over
11 	 14 	 ((S\NP)\(S\NP))/NP 	 2 	 turned in
13 	 11 	 ((S[pt]\NP)/PP)/NP 	 3 	 evidence turned
17 	 14 	 ((S\NP)\(S\NP))/NP 	 3 	 investigation in
17 	 15 	 NP[nb]/N 	 1 	 investigation a
17 	 16 	 N/N 	 1 	 investigation criminal
17 	 18 	 (S[ng]\NP)/NP 	 1 	 investigation concerning <XB>
21 	 18 	 (S[ng]\NP)/NP 	 2 	 Inc. concerning
21 	 19 	 N/N 	 1 	 Inc. Vitarine
21 	 20 	 N/N 	 1 	 Inc. Pharmaceuticals
22 	 11 	 ((S[pt]\NP)/PP)/NP 	 2 	 to turned
25 	 23 	 NP[nb]/N 	 1 	 Attorney the
25 	 24 	 N/N 	 1 	 Attorney U.S.
25 	 26 	 (NP[nb]/N)\NP 	 2 	 Attorney 's
27 	 22 	 PP/NP 	 1 	 office to
27 	 26 	 (NP[nb]/N)\NP 	 1 	 office 's
27 	 28 	 (NP\NP)/NP 	 1 	 office in
29 	 28 	 (NP\NP)/NP 	 2 	 Baltimore in
<\s>
<s id="wsj_2382.2"> 22
1 	 0 	 NP/NP 	 1 	 Vitarine Neither
1 	 16 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 Vitarine have
1 	 18 	 (S[pss]\NP)/PP 	 1 	 Vitarine charged <XB>
3 	 0 	 NP/NP 	 1 	 any Neither
3 	 4 	 (NP\NP)/NP 	 1 	 any of
3 	 16 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 any have
3 	 18 	 (S[pss]\NP)/PP 	 1 	 any charged <XB>
9 	 6 	 (N/N)/(N/N) 	 2 	 N.Y. Springfield
9 	 7 	 (N/N)/(N/N) 	 2 	 N.Y. Gardens
11 	 5 	 NP[nb]/N 	 1 	 company the
11 	 9 	 N/N 	 1 	 company N.Y.
11 	 12 	 (NP[nb]/N)\NP 	 2 	 company 's
13 	 4 	 (NP\NP)/NP 	 2 	 officials of
13 	 12 	 (NP[nb]/N)\NP 	 1 	 officials 's
15 	 4 	 (NP\NP)/NP 	 2 	 employees of
15 	 12 	 (NP[nb]/N)\NP 	 1 	 employees 's
17 	 16 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 been have
18 	 17 	 (S[pt]\NP)/(S[pss]\NP) 	 2 	 charged been
19 	 18 	 (S[pss]\NP)/PP 	 2 	 with charged
21 	 19 	 PP/NP 	 1 	 crimes with
21 	 20 	 NP[nb]/N 	 1 	 crimes any
<\s>
<s id="wsj_2382.3"> 27
0 	 1 	 (S[dcl]\NP)/NP 	 1 	 Vitarine won
0 	 13 	 (S[dcl]\NP)/S[em] 	 1 	 Vitarine acknowledged <XU>
2 	 1 	 (S[dcl]\NP)/NP 	 2 	 approval won
2 	 4 	 (S[b]\NP)/NP 	 1 	 approval market <XB>
4 	 3 	 (S[to]\NP)/(S[b]\NP) 	 2 	 market to
6 	 4 	 (S[b]\NP)/NP 	 2 	 version market
6 	 5 	 NP[nb]/N 	 1 	 version a
6 	 7 	 (NP\NP)/NP 	 1 	 version of
11 	 7 	 (NP\NP)/NP 	 2 	 medicine of
11 	 8 	 NP[nb]/N 	 1 	 medicine a
11 	 9 	 N/N 	 1 	 medicine blood
11 	 10 	 N/N 	 1 	 medicine pressure
14 	 13 	 (S[dcl]\NP)/S[em] 	 2 	 that acknowledged
15 	 16 	 ((S[dcl]\NP)/PP)/NP 	 1 	 it substituted
16 	 14 	 S[em]/S[dcl] 	 1 	 substituted that
16 	 25 	 ((S\NP)\(S\NP))/NP 	 2 	 substituted in
21 	 16 	 ((S[dcl]\NP)/PP)/NP 	 3 	 product substituted
21 	 17 	 NP[nb]/N 	 1 	 product a
21 	 18 	 N/N 	 1 	 product SmithKline
21 	 19 	 N/N 	 1 	 product Beecham
21 	 20 	 N/N 	 1 	 product PLC
22 	 16 	 ((S[dcl]\NP)/PP)/NP 	 2 	 as substituted
24 	 22 	 PP/NP 	 1 	 own as
24 	 23 	 NP[nb]/N 	 1 	 own its
26 	 25 	 ((S\NP)\(S\NP))/NP 	 3 	 tests in
<\s>
<s id="wsj_2382.4"> 21
1 	 0 	 N/N 	 1 	 Nesbit Mr.
1 	 3 	 (S[dcl]\NP)/S[dcl] 	 1 	 Nesbit said
3 	 2 	 (S\NP)/(S\NP) 	 2 	 said also
5 	 4 	 NP[nb]/N 	 1 	 FDA the
5 	 6 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 FDA has
5 	 7 	 ((S[pt]\NP)/(S[to]\NP))/NP 	 1 	 FDA asked <XB>
6 	 3 	 (S[dcl]\NP)/S[dcl] 	 2 	 has said
7 	 6 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 asked has
10 	 7 	 ((S[pt]\NP)/(S[to]\NP))/NP 	 3 	 Co. asked
10 	 8 	 N/N 	 1 	 Co. Bolar
10 	 9 	 N/N 	 1 	 Co. Pharmaceutical
10 	 12 	 (S[b]\NP)/NP 	 1 	 Co. recall <XB>
11 	 7 	 ((S[pt]\NP)/(S[to]\NP))/NP 	 2 	 to asked
12 	 11 	 (S[to]\NP)/(S[b]\NP) 	 2 	 recall to
12 	 13 	 ((S\NP)\(S\NP))/NP 	 2 	 recall at
16 	 13 	 ((S\NP)\(S\NP))/NP 	 3 	 level at
16 	 14 	 NP[nb]/N 	 1 	 level the
16 	 15 	 N/N 	 1 	 level retail
20 	 12 	 (S[b]\NP)/NP 	 2 	 antibiotic recall
20 	 17 	 NP[nb]/N 	 1 	 antibiotic its
20 	 18 	 N/N 	 1 	 antibiotic urinary
20 	 19 	 N/N 	 1 	 antibiotic tract
<\s>
<s id="wsj_2382.5"> 15
2 	 1 	 (S/S)/(S/S) 	 2 	 far so
4 	 3 	 NP[nb]/N 	 1 	 company the
4 	 5 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 company has
4 	 7 	 (S[pt]\NP)/PP 	 1 	 company complied <XB>
5 	 0 	 S/S 	 1 	 has But
5 	 2 	 S/S 	 1 	 has far
5 	 6 	 (S\NP)\(S\NP) 	 2 	 has n't
5 	 14 	 (S[dcl]\S[dcl])\NP 	 1 	 has said
7 	 5 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 complied has
8 	 7 	 (S[pt]\NP)/PP 	 2 	 with complied
10 	 8 	 PP/NP 	 1 	 request with
10 	 9 	 NP[nb]/N 	 1 	 request that
13 	 12 	 NP[nb]/N 	 1 	 spokesman the
13 	 14 	 (S[dcl]\S[dcl])\NP 	 2 	 spokesman said
<\s>
<s id="wsj_2382.6"> 49
0 	 26 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 Bolar agreed
0 	 28 	 (S[b]\NP)/NP 	 1 	 Bolar recall <XB>
3 	 2 	 NP[nb]/N 	 1 	 subject the
3 	 4 	 (NP\NP)/NP 	 1 	 subject of
3 	 26 	 (S[dcl]\NP)/(S[to]\NP) 	 1 	 subject agreed
3 	 28 	 (S[b]\NP)/NP 	 1 	 subject recall <XB>
7 	 4 	 (NP\NP)/NP 	 2 	 investigation of
7 	 5 	 NP[nb]/N 	 1 	 investigation a
7 	 6 	 N/N 	 1 	 investigation criminal
7 	 8 	 (NP\NP)/NP 	 1 	 investigation by
10 	 8 	 (NP\NP)/NP 	 2 	 FDA by
10 	 9 	 NP[nb]/N 	 1 	 FDA the
14 	 12 	 NP[nb]/N 	 1 	 General the
14 	 13 	 N/N 	 1 	 General Inspector
14 	 15 	 (NP[nb]/N)\NP 	 2 	 General 's
16 	 8 	 (NP\NP)/NP 	 2 	 office by
16 	 15 	 (NP[nb]/N)\NP 	 1 	 office 's
16 	 17 	 (NP\NP)/NP 	 1 	 office of
19 	 17 	 (NP\NP)/NP 	 2 	 Health of
19 	 18 	 NP[nb]/N 	 1 	 Health the
23 	 17 	 (NP\NP)/NP 	 2 	 Department of
23 	 18 	 NP[nb]/N 	 1 	 Department the
23 	 21 	 N/N 	 1 	 Department Human
23 	 22 	 N/N 	 1 	 Department Services
26 	 25 	 (S\NP)/(S\NP) 	 2 	 agreed only
26 	 48 	 (S[dcl]\S[dcl])\NP 	 1 	 agreed said
27 	 26 	 (S[dcl]\NP)/(S[to]\NP) 	 2 	 to agreed
28 	 27 	 (S[to]\NP)/(S[b]\NP) 	 2 	 recall to
28 	 38 	 ((S\NP)\(S\NP))/PP 	 2 	 recall down
30 	 28 	 (S[b]\NP)/NP 	 2 	 strengths recall
30 	 29 	 N/N 	 1 	 strengths two
30 	 31 	 (NP\NP)/NP 	 1 	 strengths of
33 	 31 	 (NP\NP)/NP 	 2 	 version of
33 	 32 	 NP[nb]/N 	 1 	 version its
33 	 34 	 (NP\NP)/NP 	 1 	 version of
35 	 34 	 (NP\NP)/NP 	 2 	 Macrodantin of
38 	 36 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 down as
38 	 37 	 ((S\NP)\(S\NP))/((S\NP)\(S\NP)) 	 3 	 down far
39 	 38 	 ((S\NP)\(S\NP))/PP 	 3 	 as down
41 	 39 	 PP/NP 	 1 	 customers as
41 	 40 	 N/N 	 1 	 customers direct
44 	 39 	 PP/NP 	 1 	 wholesalers as
44 	 43 	 NP/NP 	 1 	 wholesalers mostly
47 	 46 	 N/N 	 1 	 Nesbit Mr.
47 	 48 	 (S[dcl]\S[dcl])\NP 	 2 	 Nesbit said
<\s>
<s id="wsj_2382.7"> 24
0 	 2 	 (NP\NP)/NP 	 1 	 Bolar of
0 	 8 	 (S[dcl]\NP)/NP 	 1 	 Bolar began
3 	 2 	 (NP\NP)/NP 	 2 	 Copiague of
5 	 2 	 (NP\NP)/NP 	 2 	 N.Y. of
8 	 7 	 (S\NP)/(S\NP) 	 2 	 began earlier
11 	 8 	 (S[dcl]\NP)/NP 	 2 	 recall began
11 	 9 	 NP[nb]/N 	 1 	 recall a
11 	 10 	 N/N 	 1 	 recall voluntary
11 	 12 	 (NP\NP)/NP 	 1 	 recall of
16 	 15 	 (N/N)/(N/N) 	 2 	 milligram 100
19 	 18 	 (N/N)/(N/N) 	 2 	 milligram 50
20 	 12 	 (NP\NP)/NP 	 2 	 versions of
20 	 13 	 NP[nb]/N 	 1 	 versions both
20 	 14 	 NP\NP 	 1 	 versions its
20 	 16 	 N/N 	 1 	 versions milligram <XU>
20 	 19 	 N/N 	 1 	 versions milligram
20 	 21 	 (NP\NP)/NP 	 1 	 versions of
23 	 21 	 (NP\NP)/NP 	 2 	 drug of
23 	 22 	 NP[nb]/N 	 1 	 drug the
<\s>
<s id="wsj_2382.8"> 32
1 	 0 	 NP[nb]/N 	 1 	 FDA The
1 	 2 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 FDA has
1 	 3 	 (S[pt]\NP)/S[dcl] 	 1 	 FDA said <XB>
3 	 2 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 said has
4 	 5 	 (S[dcl]\NP)/NP 	 1 	 it presented
4 	 12 	 (S[ng]\NP)/S[em] 	 1 	 it indicating <XB>
5 	 3 	 (S[pt]\NP)/S[dcl] 	 2 	 presented said
5 	 9 	 ((S\NP)\(S\NP))/NP 	 2 	 presented to
6 	 5 	 (S[dcl]\NP)/NP 	 2 	 evidence presented
6 	 8 	 (S[dcl]\NP)/NP 	 2 	 evidence uncovered <XU>
7 	 8 	 (S[dcl]\NP)/NP 	 1 	 it uncovered
11 	 9 	 ((S\NP)\(S\NP))/NP 	 3 	 company to
11 	 10 	 NP[nb]/N 	 1 	 company the
13 	 12 	 (S[ng]\NP)/S[em] 	 2 	 that indicating
14 	 15 	 ((S[dcl]\NP)/PP)/NP 	 1 	 Bolar substituted
14 	 23 	 (S[b]\NP)/NP 	 1 	 Bolar gain <XB>
15 	 13 	 S[em]/S[dcl] 	 1 	 substituted that
18 	 15 	 ((S[dcl]\NP)/PP)/NP 	 3 	 product substituted
18 	 16 	 NP[nb]/N 	 1 	 product the
18 	 17 	 N/N 	 1 	 product brand-name
19 	 15 	 ((S[dcl]\NP)/PP)/NP 	 2 	 for substituted
21 	 19 	 PP/NP 	 1 	 own for
21 	 20 	 NP[nb]/N 	 1 	 own its
23 	 22 	 (S[to]\NP)/(S[b]\NP) 	 2 	 gain to
25 	 23 	 (S[b]\NP)/NP 	 2 	 approval gain
25 	 24 	 N/N 	 1 	 approval government
25 	 27 	 (S[b]\NP)/NP 	 1 	 approval sell <XB>
27 	 26 	 (S[to]\NP)/(S[b]\NP) 	 2 	 sell to
29 	 27 	 (S[b]\NP)/NP 	 2 	 versions sell
29 	 28 	 N/N 	 1 	 versions generic
29 	 30 	 (NP\NP)/NP 	 1 	 versions of
31 	 30 	 (NP\NP)/NP 	 2 	 Macrodantin of
<\s>
<s id="wsj_2382.9"> 15
0 	 1 	 (S[dcl]\NP)/(S[pt]\NP) 	 1 	 Bolar has
0 	 2 	 (S[pt]\NP)/S[em] 	 1 	 Bolar denied <XB>
2 	 1 	 (S[dcl]\NP)/(S[pt]\NP) 	 2 	 denied has
3 	 2 	 (S[pt]\NP)/S[em] 	 2 	 that denied
4 	 5 	 ((S[dcl]\NP)/PP)/NP 	 1 	 it switched
5 	 3 	 S[em]/S[dcl] 	 1 	 switched that
5 	 12 	 ((S\NP)\(S\NP))/NP 	 2 	 switched in
8 	 5 	 ((S[dcl]\NP)/PP)/NP 	 3 	 product switched
8 	 6 	 NP[nb]/N 	 1 	 product the
8 	 7 	 N/N 	 1 	 product brand-name
9 	 5 	 ((S[dcl]\NP)/PP)/NP 	 2 	 for switched
11 	 9 	 PP/NP 	 1 	 own for
11 	 10 	 NP[nb]/N 	 1 	 own its
14 	 12 	 ((S\NP)\(S\NP))/NP 	 3 	 testing in
14 	 13 	 NP/NP 	 1 	 testing such
<\s>
